Will Garner

Vice President Of Biometrics at Mirum Pharmaceuticals

Will Garner has extensive experience in the pharmaceutical industry. Will currently holds the position of Vice President of Biometrics at Mirum Pharmaceuticals, Inc. starting in February 2024. Prior to this role, they served as an Executive Director from January 2022 to February 2024 and as the Senior Director (Head) of Biometrics from January 2021 to January 2022. Will also worked as the Senior Director of Biostatistics from March 2020 to January 2021 at the same company.

Before joining Mirum Pharmaceuticals, Inc., Will Garner worked at CytomX Therapeutics as a Director from April 2019 to March 2020 and as an Associate Director from April 2018 to March 2019.

Will also gained valuable experience at Gilead Sciences, where they held various roles including Senior Manager from March 2018 to April 2018 and Manager Biostatistics from January 2016 to February 2018. Will'srole as a Sr. Biostatistician from February 2012 to January 2016 involved leading statistical analysis in multiple therapeutic areas, conducting data analyses for publications, and negotiating with customers.

Will Garner had a role as a Biostatistician at Santen from July 2011 to February 2012, where they estimated sample size, drafted statistical analysis plans, and prepared ADaM specifications for a Phase 2 study in Ophthalmology.

Prior to their industry experience, they worked as an Associate Instructor at UC San Diego from January 2010 to June 2011.

Overall, Will Garner has demonstrated progressive growth and expertise in the biometrics and biostatistics field throughout their career.

Will Garner earned a PhD in Mathematics, an MS in Statistics, and a BA in Applied Mathematics from UC San Diego.

Links

Previous companies

Gilead Sciences logo
Santen logo
CytomX logo

Timeline

  • Vice President Of Biometrics

    February, 2024 - present

  • Executive Director

    January, 2022

  • Senior Director (head) Of Biometrics

    January, 2021

  • Senior Director Of Biostatistics

    March, 2020